» Articles » PMID: 38288445

The ORFIUS Complex Regulates ORC2 Localization at Replication Origins

Overview
Journal NAR Cancer
Specialty Oncology
Date 2024 Jan 30
PMID 38288445
Authors
Affiliations
Soon will be listed here.
Abstract

High-grade serous ovarian cancer (HGSC) is a lethal malignancy with elevated replication stress (RS) levels and defective RS and RS-associated DNA damage responses. Here we demonstrate that the bromodomain-containing protein BRD1 is a RS suppressing protein that forms a replication origin regulatory complex with the histone acetyltransferase HBO1, the BRCA1 tumor suppressor, and BARD1, ORigin FIring Under Stress (ORFIUS). BRD1 and HBO1 promote eventual origin firing by supporting localization of the origin licensing protein ORC2 at origins. In the absence of BRD1 and/or HBO1, both origin firing and nuclei with ORC2 foci are reduced. BRCA1 regulates BRD1, HBO1, and ORC2 localization at replication origins. In the absence of BRCA1, both origin firing and nuclei with BRD1, HBO1, and ORC2 foci are increased. In normal and non-HGSC ovarian cancer cells, the ORFIUS complex responds to ATR and CDC7 origin regulatory signaling and disengages from origins during RS. In -mutant and sporadic HGSC cells, BRD1, HBO1, and ORC2 remain associated with replication origins, and unresponsive to RS, DNA damage, or origin regulatory kinase inhibition. ORFIUS complex dysregulation may promote HGSC cell survival by allowing for upregulated origin firing and cell cycle progression despite accumulating DNA damage, and may be a RS target.

Citing Articles

HBO1, a MYSTerious KAT and its links to cancer.

Yokoyama A, Niida H, Kutateladze T, Cote J Biochim Biophys Acta Gene Regul Mech. 2024; 1867(3):195045.

PMID: 38851533 PMC: 11330361. DOI: 10.1016/j.bbagrm.2024.195045.

References
1.
Gong F, Chiu L, Cox B, Aymard F, Clouaire T, Leung J . Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination. Genes Dev. 2015; 29(2):197-211. PMC: 4298138. DOI: 10.1101/gad.252189.114. View

2.
ODonovan P, Livingston D . BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010; 31(6):961-7. DOI: 10.1093/carcin/bgq069. View

3.
Anglesio M, Wiegand K, Melnyk N, Chow C, Salamanca C, Prentice L . Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 2013; 8(9):e72162. PMC: 3762837. DOI: 10.1371/journal.pone.0072162. View

4.
Sun C, Yin J, Fang Y, Chen J, Jeong K, Chen X . BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell. 2018; 33(3):401-416.e8. PMC: 5944839. DOI: 10.1016/j.ccell.2018.01.019. View

5.
Konstantinopoulos P, da Costa A, Gulhan D, Lee E, Cheng S, Wahner Hendrickson A . A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021; 12(1):5574. PMC: 8458434. DOI: 10.1038/s41467-021-25904-w. View